Randomized placebo-controlled trial of the bradykinin B2receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial

The For Angioedema Subcutaneous Treatment (FAST)-3 study was a phase III, randomized, double-blind, placebo-controlled study of icatibant (bradykinin B2receptor antagonist) in subjects with hereditary angioedema (HAE) resulting from C1-INH deficiency or dysfunction (type I/II).